ANTIMICROBIAL TECHNOLOGIES & DRUG DELIVERY PLATFORMS
With
Associate Professor Aaron Elbourne, RMIT University, Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | January 2026
Dr Aaron Elbourne is an ARC DECRA Fellow, Jack Brockhoff ECR Fellow, and Associate Professor within the School of Science at STEM Hub. A leader in nanomaterials, soft matter science, and interface research, Aaron’s work addresses critical challenges in health and the environment.
Since becoming an independent researcher, Aaron has held continuous funding from prestigious funders, including the Australian Research Council (ARC) and the National Health and Medical Research Council (NHMRC). His research is characterised by its interdisciplinary approach, combining chemistry, materials science, and engineering. His pioneering contributions to colloid therapeutics and soft matter science have driven advancements in diagnostic tools, antimicrobial technologies, and therapeutic delivery systems. His expertise in studying nanomaterial interactions with synthetic and biological membranes has been instrumental in translating scientific discoveries into impactful applications.
Aaron is a dedicated mentor to early-career researchers (ECRs) and students, having supervised and trained numerous postgraduate and doctoral candidates. He has played a key role in securing funding for student training initiatives, including joint PhD scholarships and National Industry PhD programs, which emphasise collaboration between academia and industry.
With a strong focus on translational research, Aaron’s work bridges the gap between fundamental science and practical applications. His leadership in creating innovative technologies, fostering academic-industry partnerships, and empowering future researchers underscores his commitment to advancing science and creating a meaningful impact.
Source: Supplied
https://orcid.org/0000-0002-8562-7325
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
-
Supportive care for people living with or beyond cancer treatment
Dr Hannah Wardill is a Hospital Research Foundation Fellow and lead of the Supportive Oncology Research Group (SORG), in the School of Biomedicine, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI). She is an Executive Board Member of the Multinational Association for Supportive Care in Cancer / International Society for Oral Oncology (MASCC/ISOO) and Chair of both MASCC/ISOO Patient Partnership Committee & the Palliative Care Clinical Studies Collaborative (PaCCSC) Cancer Symptom Trials (Gut Dysfunction Node; supported by Cancer Australia).
